LEGN Legend Biotech (LEGN) Q4 FY25 earnings call
Legend Biotech concluded FY25 as a leading cell therapy company, driven by the strong commercial performance and expanding global footprint of CARVYKTI. The company achieved CARVYKTI profitability in 2025 and anticipates company-wide profitability in 2026, supported by disciplined expense management and a robust balance sheet. Strategic focus remains on expanding CARVYKTI's use in earlier treatment lines and advancing a next-generation R&D pipeline, including in vivo CAR-T programs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
LEGN operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Global treatment sites | 294Our global growth was driven by continued share gains, site expansion and growing geographic footprint, now reaching 294 global treatment sites across 14 markets worldwide.Source: earnings call transcript | 300+Outside the US demand was supported by continued uptake in established European markets and contributions from recent launches with CARVYKTI now available across 18 global markets and more than 300 global treatment sites.Source: earnings call transcript | 348We recently launched CARVYKTI in Ireland, further expanding availability to 348 global treatment sites, reflecting continued geographic expansion with our partner, J&J Across geographies, we continue to see encouraging trends in both market penetration and earlier line utilization.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.